Home » Stocks » CARA

Cara Therapeutics, Inc. (CARA)

Stock Price: $18.56 USD 0.51 (2.83%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $18.50 -0.06 (-0.32%) Jan 15, 5:38 PM
Market Cap 926.38M
Revenue (ttm) 27.50M
Net Income (ttm) -99.11M
Shares Out 46.89M
EPS (ttm) -2.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $18.56
Previous Close $18.05
Change ($) 0.51
Change (%) 2.83%
Day's Open 18.06
Day's Range 18.04 - 18.78
Day's Volume 523,942
52-Week Range 9.12 - 18.78

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 week ago

Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.

GlobeNewsWire - 1 week ago

STAMFORD, Conn., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed ...

InvestorPlace - 2 weeks ago

These 6 cannabis stocks show promise in the medical and recreational ends of the burgeoning marijuana sector, set to grow even more in 2021. The post 6 Cannabis Stocks to Buy as the U.S. Softe...

Other stocks mentioned: CGC, GRWG, MRK, SNY, TRSSF
GlobeNewsWire - 2 weeks ago

STAMFORD, Conn., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed ...

Seeking Alpha - 4 weeks ago

The opioid industry is an ~$50 billion annual business, but opioids are very harmful to the body and extremely addictive. CARA has a drug that is finishing its trials and expectation is that a...

GlobeNewsWire - 1 month ago

- Topline data expected in first half of 2021 -

GlobeNewsWire - 2 months ago

STAMFORD, Conn., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed ...

Seeking Alpha - 2 months ago

Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Cara (CARA) delivered earnings and revenue surprises of 48.53% and 86.25%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 2 months ago

– Conference call today at 4:30 p.m. ET –

GlobeNewsWire - 2 months ago

STAMFORD, Conn., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed ...

Zacks Investment Research - 2 months ago

Cara (CARA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 2 months ago

- Results from global KALM-2 p ivotal Phase 3 t rial of KORSUVA ™ Injection in h emodialysis p atients with p ruritus to be presented –

Business Wire - 2 months ago

ST GALLEN, Switzerland & STAMFORD, Conn.--(BUSINESS WIRE)--Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with pruritus

GlobeNewsWire - 2 months ago

- Cara to Host Conference Call Today at 8:30 am EDT -

GlobeNewsWire - 3 months ago

STAMFORD, Conn., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed ...

Seeking Alpha - 5 months ago

Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Cara (CARA) delivered earnings and revenue surprises of 20.59% and 2.90%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

– Conference call today at 4:30 p.m. ET –

GlobeNewsWire - 5 months ago

STAMFORD, Conn., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designe...

GlobeNewsWire - 5 months ago

STAMFORD, Conn., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed...

Zacks Investment Research - 5 months ago

Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investopedia - 6 months ago

These marijuana stocks on the Nasdaq are top for value, growth, and performance for July 2020.

Other stocks mentioned: AMRS, CRON, GWPH, TLRY
GlobeNewsWire - 6 months ago

STAMFORD, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designe...

The Motley Fool - 6 months ago

Both of these biotechs could have big catalysts on the way.

Other stocks mentioned: GWPH
The Motley Fool - 6 months ago

These companies are all surprising a few doubters lately.

Other stocks mentioned: ARNA, FMS
The Motley Fool - 6 months ago

Here are seven straightforward steps to help you invest in high-growth -- but high-risk -- marijuana stocks.

Other stocks mentioned: ACB, APHA, CGC, CRBP, CRON, GWPH, HEXO, MJ, OGI, SMG, TLRY
GlobeNewsWire - 6 months ago

- Patient enrollment increased approximately 28% to maintain > 80% statistical power for primary endpoint and key registration endpoint of  > 4-point improvement responder analysis -

Investopedia - 7 months ago

These are the NASDAQ-listed marijuana stocks with the best value, fastest growth, and most momentum for June.

Other stocks mentioned: GWPH, VFF
Zacks Investment Research - 8 months ago

Cara Therapeutics (CARA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Seeking Alpha - 8 months ago

Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Cara (CARA) delivered earnings and revenue surprises of 1.59% and 67.56%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

The Motley Fool - 8 months ago

Which stock wins in a battle between these two clinical-stage biotechs?

Other stocks mentioned: SGMO
Zacks Investment Research - 8 months ago

Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 8 months ago

The company plans to submit its pruritis drug for FDA and EMA approval later this year.

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor in Cara Therapeutics.

GlobeNewsWire - 8 months ago

STAMFORD, Conn. and ST. GALLEN, Switzerland, April 21, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA) and Vifor Fresenius Medical Care Renal Pharma (VFMCRP), today announced ...

Other stocks mentioned: FMS
GlobeNewsWire - 9 months ago

- On track to report topline data for KALM-2 Phase 3 global trial of  KORSUVA™ Injection in second quarter –                   

Seeking Alpha - 10 months ago

Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Cara (CARA) delivered earnings and revenue surprises of 1.61% and -19.13%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

The Motley Fool - 10 months ago

These stocks went in opposite directions in 2019. Will that trend continue this year?

Other stocks mentioned: SMG
The Motley Fool - 11 months ago

These pharma stocks have gone in different directions in the last year, but both hold promise for forward-thinking investors.

Other stocks mentioned: TGTX
The Motley Fool - 11 months ago

Despite their differences, there's a lot of good things going on for both of these health companies.

Other stocks mentioned: GWPH
Investopedia - 11 months ago

The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges.

Other stocks mentioned: ARNA, CRBP, CRON, GNLN, GWPH, MBII, NBEV, NTEC, OGI, PMD, SNDL, TLRY, TRPX, VFF, ZYNE
The Motley Fool - 11 months ago

What does the future look like for this promising biotech stock?

Seeking Alpha - 1 year ago

Cara Therapeutics Is An Undervalued Asset In 2020

GlobeNewsWire - 1 year ago

STAMFORD, Conn., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a ...

The Motley Fool - 1 year ago

Small-cap stocks have been subpar performers of late, but that weakness has only made the opportunity more compelling.

Other stocks mentioned: ADVM, CAMP, GDOT, IIPR, IWM, MFMS, SPY, VIOO
The Motley Fool - 1 year ago

These two companies could be headed in vastly different directions in 2020.

Other stocks mentioned: FMS
The Motley Fool - 1 year ago

Both of these biotechs could become smash hits, but which is better?

Other stocks mentioned: CRBP

About CARA

Cara Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated ... [Read more...]

Industry
Biotechnology
IPO Date
Jan 31, 2014
CEO
Derek Chalmers
Employees
76
Stock Exchange
NASDAQ
Ticker Symbol
CARA
Full Company Profile

Financial Performance

In 2019, CARA's revenue was $19.89 million, an increase of 47.64% compared to the previous year's $13.47 million. Losses were -$106.37 million, 43.7% more than in 2018.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for CARA stock is "Buy." The 12-month stock price forecast is 33.13, which is an increase of 78.50% from the latest price.

Price Target
$33.13
(78.50% upside)
Analyst Consensus: Buy